Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma

INTRODUCTION: Outcomes remain poor in patients with diffuse large B cell lymphoma (DLBCL) who overexpress BCL-2 protein. We present population pharmacokinetics (PopPK) and exposure–response (ER) analyses for venetoclax (a selective BCL-2 inhibitor) administered with rituximab-cyclophosphamide, doxor...

Descripción completa

Detalles Bibliográficos
Autores principales: Samineni, Divya, Huang, Weize, Gibiansky, Leonid, Ding, Hao, Zhang, Rong, Li, Chunze, Sinha, Arijit, Rajwanshi, Richa, Humphrey, Kathryn, Bazeos, Alexandra, Salem, Ahmed Hamed, Miles, Dale
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799559/
https://www.ncbi.nlm.nih.gov/pubmed/34822104
http://dx.doi.org/10.1007/s12325-021-01919-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799559/
https://www.ncbi.nlm.nih.gov/pubmed/34822104
http://dx.doi.org/10.1007/s12325-021-01919-z

Ejemplares similares